AOL Money & Finance

LungCancer posts

Feed

What you don't know about your microwave popcorn could kill you

PopcornThe Associated Press reports that America's largest popcorn maker, ConAgra Foods (NYSE: CAG), has been poisoning the lungs of its popcorn plant workers and will take its time solving the problem. Specifically, ConAgra will change the recipe for its Orville Redenbacher and Act II brands over the next year to remove the flavoring chemical diacetyl, linked to a lung ailment in popcorn plant workers.

The decision comes a day after a doctor at a leading lung research hospital said in a warning letter to federal regulators that consumers, not just factory workers, may be in danger from fumes from buttery flavoring in microwave popcorn.

The timing of this decision suggests that ConAgra has no problem poisoning its workers. But it seems to care a bit more about poisoning its customers. After all, if all its customers get lung disease and die, who will pay for the popcorn? I guess ConAgra feels comfortable that its employees can always be replaced.

I wonder whether ConAgra is concerned that its employees will sue the company for unsafe working conditions? Or will microwave popcorn eaters will rise up and sue ConAgra for lung poisoning? Meanwhile ConAgra's planned slow pace of replacing the flavoring chemical guarantees that I will keep its products out of my kitchen for a long, long time.

Peter Cohan is President of Peter S. Cohan & Associates. He also teaches management at Babson College and edits The Cohan Letter.

Coley Pharmaceutical drug given the ax

Earlier this afternoon, Coley Pharmaceutical Group Inc (NASDAQ: COLY) announced that Pfizer Inc (NYSE: PFE) would discontinue the development program of an investigational drug compound - PF-3512676 - in combination with cytotoxic chemotherapy for the treatment of lung cancer. After two Phase 3 clinical trials and two Phase 2 clinical trials, an analysis by an independent Data Safety Monitoring Committee found that there was "no evidence that PF-3513676 produced additional clinical efficacy over that achieved" with cytotoxic chemotherapy alone. The DSMC said that the "risk-benefit profile did not justify continuation" of the compound trial, and Pfizer, apparently, agreed.

This news comes as a huge blow to Coley, whose main thesis drug is PF-3512676, and who is trying to become a force-to-reckon-with in the oncology field. In a statement, president and CEO Robert L. Bratzler, Ph.D., said that the announcement was "surprising, based on the signs of clinical activity observed."

On the announcement, shares of Coley were down approximately 60%. As of March 31, the company had $3.35 per share in cash. Coley will be hosting a conference call and webcast this afternoon at 4:30 p.m. (EST) to discuss this development.

Symbol Lookup
IndexesChangePrice
DJIA+20.0310,246.97
NASDAQ-2.982,151.08
S&P 500-0.071,093.01

Last updated: November 11, 2009: 07:51 AM

BloggingStocks Exclusives

Hot Stocks

DailyFinance Headlines

Latest from BloggingBuyouts

WalletPop Headlines

AOL Business News

BioHealth Investor Headlines

Sponsored Links

My Portfolios

Track your stocks here!

Find out why more people track their portfolios on AOL Money & Finance then anywhere else.

BloggingStocks Partners

More from AOL Money & Finance